In Brussels today, IPPOSI’s CEO Derick Mitchell was part of a delegation that met with members of the EU Article 50 Taskforce negotiating team from the European Commission, to advocate for the protection of the health and safety of EU and UK patients during the Brexit negotiations.
The delegation included IPPOSI, the European Patients’ Forum (EPF), the Association of Medical Research Charities (AMRC), and Cancer Research UK and represented signatories of this open letter signed by a consortium of pan-EU and UK-based patient-led organisations (more information here) in order to raise concerns about the impact of Brexit on patients in the EU and UK.
Today’s meeting was with Mr. Stephan Fuehring and a number of other members of the Article 50 Taskforce. At today’s meeting the focus was on:
- Pan-European clinical trials
- Cross-border healthcare initiatives
- Collaborative medical research, with particular emphasis on rare diseases (European Reference Networks)
- Regulation of Medicines, with particular emphasis on dual-labelling
Pictured above are (L-R):
Dr Derick Mitchell, Chief Executive, IPPOSI; Susanna Palkonen, EPF and Director, European Federation of Allergy and Airways Diseases Patients Associations; Kostas Aligiannis, Policy Officer, EPF; Dr Cat Ball, Policy Manager, AMRC; Prof Pamela Kearns, Director of the Cancer Research UK Clinical Trials Unit in the School of Cancer Sciences, University of Birmingham.
IPPOSI will continue to keep our members updated on these (and other parallel) efforts to bring a concerted, unified patient voice to the Brexit negotiation process.
A summary note of the meeting discussions will follow shortly on this page.